Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma

Meyer Children's Hospital IRCCS

Status: Completed

Conditions: Neuroblastoma; Ewing Sarcoma

Treatments: Diagnostic Test: beta3 expression

Study type: Interventional

Funder types: Other

Identifiers

NCT06851221

BETA3TumPed

Details and patient eligibility

About

This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.

Enrollment: 95 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of Ewing sarcoma or neuroblastoma

Exclusion criteria

• sieropositivity

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

95 participants in 1 patient group

biological samples analysis

Other group

Treatment:

Diagnostic Test: beta3 expression